The earnings call reflects a positive outlook with significant progress in clinical programs and financial stability, despite some increased operational expenses.

Company Guidance -

Q2 2025

During DiaMedica Therapeutics' First Quarter 2025 Conference Call, the company provided guidance on their preeclampsia and stroke programs. They are nearing completion of Part 1a of their Phase 2 preeclampsia trial, focusing on safety, blood pressure reduction, and uterine blood flow metrics, with preliminary results expected between late June and early July. The stroke program has reached 20-25% enrollment for interim analysis, with results targeted for the first half of 2026. Financially, DiaMedica reported $37.3 million in cash and investments at the end of March 2025, with a net cash usage of $7.1 million in Q1, and anticipates that current funds will last into Q3 of 2026.

Progress in Preeclampsia Program

DiaMedica is close to identifying a target dose for its Phase 2 preeclampsia trial, with preliminary top-line results expected between late June and early July.

Steady Enrollment in Stroke Program

Participant enrollment in the stroke program is progressing, with enrollment between the 20th and 25th percentile for interim analysis.

Financial Stability

DiaMedica reported a total combined cash and investments of $37.3 million as of March 31, 2025, providing a runway into Q3 of 2026.

Increased R&D Investment

Research and development expenses increased to $5.7 million for Q1 2025, primarily due to the continuation of the ReMEDy2 clinical trial and global expansion.

Diamedica Therapeutics (DMAC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DMAC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2025	2025 (Q2)	-0.19 / -	-0.13	―	―	―
May 13, 2025	2025 (Q1)	-0.18 / -0.18	-0.14	-28.57% (-0.04)	―
Mar 17, 2025	2024 (Q4)	-0.17 / -0.18	-0.12	-50.00% (-0.06)	―
Nov 13, 2024	2024 (Q3)	-0.15 / -0.15	-0.12	-25.00% (-0.03)	―
Aug 07, 2024	2024 (Q2)	-0.16 / -0.13	-0.16	18.75% (+0.03)	―
May 08, 2024	2024 (Q1)	-0.16 / -0.14	-0.2	30.00% (+0.06)	―
Mar 19, 2024	2023 (Q4)	-0.14 / -0.12	-0.14	14.29% (+0.02)	―
Nov 13, 2023	2023 (Q3)	-0.13 / -0.12	-0.12	0.00% (0.00)	―
Aug 14, 2023	2023 (Q2)	-0.18 / -0.16	-0.13	-23.08% (-0.03)	―
May 15, 2023	2023 (Q1)	-0.16 / -0.20	-0.13	-53.85% (-0.07)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DMAC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2025	$3.98	$4.00	+0.50%
Mar 17, 2025	$5.99	$5.21	-13.02%
Nov 13, 2024	$4.26	$4.12	-3.29%
Aug 07, 2024	$3.25	$3.35	+3.08%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Diamedica Therapeutics Inc (DMAC) report earnings?

Diamedica Therapeutics Inc (DMAC) is schdueled to report earning on Aug 06, 2025, TBA (Confirmed).

What is Diamedica Therapeutics Inc (DMAC) earnings time?

Diamedica Therapeutics Inc (DMAC) earnings time is at Aug 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DMAC EPS forecast?

DMAC EPS forecast for the fiscal quarter 2025 (Q2) is -0.19.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing